Nanomedicine for Increasing the Oral Bioavailability of Cancer Treatments

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2021 Oct 31

PMID 34717658

Citations 34

Authors

Alessandro Parodi

Polina Buzaeva

Daria Nigovora

Alexey Baldin

Dmitry Kostyushev

Vladimir Chulanov

Lyudmila V Savvateeva

Andrey A Zamyatnin Jr

Affiliations

Soon will be listed here.

Abstract

Oral administration is an appealing route of delivering cancer treatments. However, the gastrointestinal tract is characterized by specific and efficient physical, chemical, and biological barriers that decrease the bioavailability of medications, including chemotherapeutics. In recent decades, the fields of material science and nanomedicine have generated several delivery platforms with high potential for overcoming multiple barriers associated to oral administration. This review describes the properties of several nanodelivery systems that improve the bioavailability of orally administered therapeutics, highlighting their advantages and disadvantages in generating successful anticancer oral nanomedicines.

Citing Articles

Oral Administration of Neratinib Maleate-Loaded Lipid-Polymer Hybrid Nanoparticles: Optimization, Physical Characterization, and In Vivo Evaluation.

Mahajan R, Ravi P, Jadhav S, Pansuriya P, Naik B, Anture S Pharmaceutics. 2025; 17(2).

PMID: 40006588 PMC: 11858839. DOI: 10.3390/pharmaceutics17020221.

Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Su Y, Liu L, Lin C, Deng D, Li Y, Huang M Front Pharmacol. 2024; 15:1476739.

PMID: 39691396 PMC: 11649421. DOI: 10.3389/fphar.2024.1476739.

Functional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications.

Gao S, Sui Z, Jiang Q, Jiang Y Int J Nanomedicine. 2024; 19:10283-10305.

PMID: 39403709 PMC: 11472738. DOI: 10.2147/IJN.S480639.

Enteral Route Nanomedicine for Cancer Therapy.

Zhang L, Du R, Wang D, Qin J, Yu C, Zhang L Int J Nanomedicine. 2024; 19:9889-9919.

PMID: 39351000 PMC: 11439897. DOI: 10.2147/IJN.S482329.

Solubilization of Paclitaxel with Natural Compound Rubusoside toward Improving Oral Bioavailability in a Rodent Model.

Zhang J, Shu J, Stout R, Russo P, Liu Z Pharmaceutics. 2024; 16(8).

PMID: 39204449 PMC: 11359394. DOI: 10.3390/pharmaceutics16081104.

References

Rowland A, van Dyk M, Mangoni A, Miners J, McKinnon R, Wiese M . Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opin Drug Metab Toxicol. 2016; 13(1):31-49. DOI: 10.1080/17425255.2016.1229303. View

Kim M, Kim J, Lee J, Jia H, Na H, Youn J . Crosslinked enzyme aggregates in hierarchically-ordered mesoporous silica: a simple and effective method for enzyme stabilization. Biotechnol Bioeng. 2006; 96(2):210-8. DOI: 10.1002/bit.21107. View

Betker J, Angle B, Graner M, Anchordoquy T . The Potential of Exosomes From Cow Milk for Oral Delivery. J Pharm Sci. 2018; 108(4):1496-1505. PMC: 6788294. DOI: 10.1016/j.xphs.2018.11.022. View

Ruan L, Chen S, Yu B, Zhu D, Cordell G, Qiu S . Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem. 2006; 41(5):605-10. DOI: 10.1016/j.ejmech.2006.01.013. View

Ren T, Wang Q, Xu Y, Cong L, Gou J, Tao X . Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles. J Control Release. 2017; 269:423-438. DOI: 10.1016/j.jconrel.2017.11.015. View

Berardi A, Bombelli F . Oral delivery of nanoparticles - let's not forget about the protein corona. Expert Opin Drug Deliv. 2019; 16(6):563-566. DOI: 10.1080/17425247.2019.1610384. View

Liu N, Brown A, Folias A, Younge M, Guzman S, Close K . Stigma in People With Type 1 or Type 2 Diabetes. Clin Diabetes. 2017; 35(1):27-34. PMC: 5241772. DOI: 10.2337/cd16-0020. View

Porter C, Charman W . Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev. 2001; 50(1-2):1-2. DOI: 10.1016/s0169-409x(01)00146-6. View

Mandracchia D, Trapani A, Tripodo G, Perrone M, Giammona G, Trapani G . In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition. Carbohydr Polym. 2017; 166:73-82. DOI: 10.1016/j.carbpol.2017.02.096. View

10.

Sonkusre P . Specificity of Biogenic Selenium Nanoparticles for Prostate Cancer Therapy With Reduced Risk of Toxicity: An and Study. Front Oncol. 2020; 9:1541. PMC: 6978793. DOI: 10.3389/fonc.2019.01541. View

11.

Maisel K, Ensign L, Reddy M, Cone R, Hanes J . Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2014; 197:48-57. PMC: 4272879. DOI: 10.1016/j.jconrel.2014.10.026. View

12.

Planas J, Alfaras I, Colom H, Juan M . The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys. 2012; 527(2):67-73. DOI: 10.1016/j.abb.2012.06.004. View

13.

Langer K, Anhorn M, Steinhauser I, Dreis S, Celebi D, Schrickel N . Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm. 2007; 347(1-2):109-17. DOI: 10.1016/j.ijpharm.2007.06.028. View

14.

Alam M, Al-Jenoobi F, Al-Mohizea A . Everted gut sac model as a tool in pharmaceutical research: limitations and applications. J Pharm Pharmacol. 2012; 64(3):326-36. DOI: 10.1111/j.2042-7158.2011.01391.x. View

15.

Diab R, Canilho N, Pavel I, Haffner F, Girardon M, Pasc A . Silica-based systems for oral delivery of drugs, macromolecules and cells. Adv Colloid Interface Sci. 2017; 249:346-362. DOI: 10.1016/j.cis.2017.04.005. View

16.

Yildiz H, McKelvey C, Marsac P, Carrier R . Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids. J Drug Target. 2015; 23(7-8):768-74. PMC: 4874559. DOI: 10.3109/1061186X.2015.1086359. View

17.

Levy M, Kolodziejczyk A, Thaiss C, Elinav E . Dysbiosis and the immune system. Nat Rev Immunol. 2017; 17(4):219-232. DOI: 10.1038/nri.2017.7. View

18.

Venkateswarlu V, Manjunath K . Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004; 95(3):627-38. DOI: 10.1016/j.jconrel.2004.01.005. View

19.

Wang T, Luo Y . Biological fate of ingested lipid-based nanoparticles: current understanding and future directions. Nanoscale. 2019; 11(23):11048-11063. DOI: 10.1039/c9nr03025e. View

20.

Roos C, Westergren J, Dahlgren D, Lennernas H, Sjogren E . Mechanistic modelling of intestinal drug absorption - The in vivo effects of nanoparticles, hydrodynamics, and colloidal structures. Eur J Pharm Biopharm. 2018; 133:70-76. DOI: 10.1016/j.ejpb.2018.10.006. View